Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Sarah E Smith-Jeffcoat und 36 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Ritonavir, Viral Load, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: RVTN, CDC HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus disease 2019 (COVID-19); however, rebound after treatment has been reported. We compared symptom and viral dynamics in individuals with COVID-19 who completed N/R treatment and similar untreated individuals.
Methods
We identified symptomatic participants who tested severe acute respiratory syndrome coronavirus 2–positive and were N/R eligible from a COVID-19 household transmission study. Index cases from ambulatory settings and their households contacts were enrolled. We collected daily symptoms, medication use, and respiratory specimens for quantitative polymerase chain reaction for 10 days during March 2022—May 2023. Participants who completed N/R treatment (treated) were propensity score matched to untreated participants. We compared symptom rebound, viral load (VL) rebound, average daily symptoms, and average daily VL by treatment status measured after N/R treatment completion or 7 days after symptom onset if untreated.
Results
Treated (n = 130) and untreated participants (n = 241) had similar baseline characteristics. After treatment completion, treated participants had greater occurrence of symptom rebound (32% vs 20%; P = .009) and VL rebound (27% vs 7%; P < .001). Average daily symptoms were lower among treated participants without symptom rebound (1.0 vs 1.6; P < .01) but not statistically lower with symptom rebound (3.0 vs 3.4; P = .5). Treated participants had lower average daily VLs without VL rebound (0.9 vs 2.6; P < .01) but not statistically lower with VL rebound (4.8 vs 5.1; P = .7).
Conclusions
Individuals who completed N/R treatment experienced fewer symptoms and lower VL but rebound occured more often compared with untreated individuals. Providers should prescribe N/R, when indicated, and communicate rebound risk to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Westat, Rockville, Maryland, USA.
- Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
- Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, New York, USA.
ORCID-Profile: Sarah E Smith-Jeffcoat, Jessica E Biddle, H Keipp Talbot, Kerry Grace Morrissey, Melissa S Stockwell, Yvonne Maldonado, Huong Q McLean, Katherine D Ellingson, Natalie M Bowman, Edwin Asturias, Alexandra M Mellis, Sheroi Johnson, Hannah L Kirking, Melissa A R Rolfes, Lori Merrill, Steph Battan-Wraith, Ellen Sano, Son H McLaren, Clea C Sarnquist, Joshua G Petrie, Edward A Belongia, Karen Lutrick, Suchitra Rao, Phillip P Salvatore
Förderung
- RVTN
- CDC HHS
- NIAID NIH HHS
- Vanderbilt University Medical Center
- Intramural CDC HHS
- Trustees of Columbia University
- CDC
Zitieren
APA
Smith-Jeffcoat, S. E., Biddle, J. E., Talbot, H. K., Morrissey, K. G., Stockwell, M. S., Maldonado, Y., McLean, H. Q., Ellingson, K. D., Bowman, N. M., Asturias, E., Mellis, A. M., Johnson, S., Kirking, H. L., Rolfes, M. A. R., Olivo, V., Merrill, L., Battan-Wraith, S., Sano, E., McLaren, S. H., …, & Salvatore, P. P. (2024). Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad696
Vancouver
Smith-Jeffcoat SE, Biddle JE, Talbot HK, Morrissey KG, Stockwell MS, Maldonado Y, et al. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad696
BibTeX
@article{SmithJeffcoat2024,
author = {Smith-Jeffcoat, Sarah E and Biddle, Jessica E and Talbot, H Keipp and Morrissey, Kerry Grace and Stockwell, Melissa S and Maldonado, Yvonne and McLean, Huong Q and Ellingson, Katherine D and Bowman, Natalie M and Asturias, Edwin and Mellis, Alexandra M and Johnson, Sheroi and Kirking, Hannah L and Rolfes, Melissa A R and Olivo, Vanessa and Merrill, Lori and Battan-Wraith, Steph and Sano, Ellen and McLaren, Son H and Vargas, Celibell Y and Goodman, Sara and Sarnquist, Clea C and Govindaranjan, Prasanthi and Petrie, Joshua G and Belongia, Edward A and Ledezma, Karla and Pryor, Kathleen and Lutrick, Karen and Bullock, Ayla and Yang, Amy and Haehnel, Quenla and Rao, Suchitra and Zhu, Yuwei and Schmitz, Jonathan and Hart, Kimberly and Grijalva, Carlos G and Salvatore, Phillip P},
title = {Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad696}
}
EUVIMED